In summary, our study has unraveled the intricate mechanisms through which KRAS mutations orchestrate the ERK/JNK signaling pathways, posttranslational modifications of ALKBH5, and mRNA m6A modification to confer platinum resistance in NSCLC cells. The gene discussed is ALKBH5; the disease is non-small cell lung carcinoma.